DRiving STandard-of-care CAR T cells in real-world Germany

maintenance therapy with prophylactic DLIs 7 or TKI 8 or parameter-driven preemptive intervention 9 in this high-risk population.This notion is supported by the single patient in the study who received a third CAR-DLI following MRDrelapse after second CAR-DLI: after CR was achieved, a TKI maintenance was initiated and resulted in a survival of around 2.5 years.In summary, the study comprehensively analyzed an allogeneic CAR-T therapybased approach for B-ALL relapse after alloHSCT demonstrating the need for LD in these patients.And last but not least, 2 patients treated in the study are alive and in remission for more than 5 years after treatment.This encourages all efforts we can muster to improve the therapeutic options, thus aiming to help our patients in this situation.